Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD

Equitable Trust Co. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 188.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,463 shares of the biopharmaceutical company’s stock after acquiring an additional 32,310 shares during the period. Equitable Trust Co.’s holdings in Gilead Sciences were worth $6,071,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the third quarter worth approximately $26,000. Ares Financial Consulting LLC acquired a new stake in Gilead Sciences during the fourth quarter worth approximately $28,000. Financial Consulate Inc. lifted its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its position in Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 86 shares during the last quarter. Finally, MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 178,640 shares of company stock worth $26,584,250 over the last three months. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GILD shares. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Oppenheimer raised their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Leerink Partners raised their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Finally, Truist Financial lifted their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Stock Up 0.6%

NASDAQ GILD opened at $133.48 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The company has a 50 day moving average of $140.14 and a 200-day moving average of $132.66. The company has a market cap of $165.68 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 1.75 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the business earned $1.90 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead’s Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. (NASDAQ:GILD) Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead’s HIV prevention shot rises, but US insurance gaps remain

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.